Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice

Cellular and Molecular Life Sciences

Volumn 71, Issue 12, 2014, Pages 2347-2357

  Lerner, Immanuel ^a   Zcharia, Eyal ^a   Neuman, Tzahi ^a   Hermano, Esther ^a   Rubinstein, Ariel M ^a   Vlodavsky, Israel ^b   Elkin, Michael ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Heparan sulfate; Heparanase; Inflammation; Psoriasis

Indexed keywords

CYCLIN D1; GAMMA INTERFERON; HEPARANASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 23; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DERMATITIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MACROPHAGE; MALE; MORPHOLOGY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSORIASIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY;

ANIMALS; CASE-CONTROL STUDIES; DERMATITIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PHENOTYPE; PSORIASIS; SKIN;

EID: 84901690129     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-013-1496-9     Document Type: Article

References (76)

1. Griffiths CE, Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370:263-271 (Pubitemid 47069537)
2. Nickoloff BJ, Qin JZ, Nestle FO (2007) Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 33:45-56 (Pubitemid 351514147)
3. Nikaein A, Phillips C, Gilbert SC, Savino D, Silverman A et al (1991) Characterization of skin-infiltrating lymphocytes in patients with psoriasis. J Invest Dermatol 96:3-9
4. Clark RA, Kupper TS (2006) Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 116:2084-2087 (Pubitemid 44162315)
5. Marble DJ, Gordon KB, Nickoloff BJ (2007) Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 48:87-101 (Pubitemid 47381571)
6. Wagner EF, Schonthaler HB, Guinea-Viniegra J, Tschachler E (2010) Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 6:704-714
7. Bishop JR, Schuksz M, Esko JD (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446:1030-1037 (Pubitemid 46676065)
8. Timpl R (1996) Macromolecular organization of basement membranes. Curr Opin Cell Biol 8:618-624 (Pubitemid 26381718)
9. Sanderson RD (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12:89-98
10. Timar J, Lapis K, Dudas J, Sebestyen A, Kopper L et al (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12:173-186 (Pubitemid 34833061)
11. Parish CR (2006) The role of heparan sulphate in inflammation. Nat Rev Immunol 6:633-643 (Pubitemid 44298213)
12. Li JP, Vlodavsky I (2009) Heparin, heparan sulfate and heparanase in inflammatory reactions. Thromb Haemost 102:823-828
13. Tomas D, Vucic M, Situm M, Kruslin B (2008) The expression of syndecan-1 in psoriatic epidermis. Arch Dermatol Res 300:393-395
14. Seyger MM, van den Born J, Schalkwijk J, van de Kerkhof PC, de Jong EM (1997) Altered distribution of heparan sulfate proteoglycans in psoriasis. Acta Derm Venereol 77:105-109 (Pubitemid 27201984)
15. Wang L, Fuster M, Sriramarao P, Esko JD (2005) Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6:902-910 (Pubitemid 43090445)
16. Axelsson J, Xu D, Kang BN, Nussbacher JK, Handel TM et al (2012) Inactivation of heparan sulfate 2-O-sulfotransferase accentuates neutrophil infiltration during acute inflammation in mice. Blood 120:1742-1751
17. Vreys V, David G (2007) Mammalian heparanase: what is the message? J Cell Mol Med 11:427-452 (Pubitemid 47153456)
18. Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L et al (2008) Heparanase: one molecule with multiple functions in cancer progression. Connect Tissue Res 49:207-210
19. Edovitsky E, Lerner I, Zcharia E, Peretz T, Vlodavsky I et al (2006) Role of endothelial heparanase in delayed-type hypersensitivity. Blood 107:3609-3616
20. Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T et al (2009) Heparanase alters arterial structure, mechanics, and repair following endovascular stenting in mice. Circ Res 104:380-387
21. Lerner I, Hermano E, Zcharia E, Rodkin D, Bulvik R et al (2011) Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice. J Clin Invest 121:1709-1721
22. Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ et al (2012) The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med 18:1217-1223
23. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE et al (2008) Dramatic regulation of heparanase activity and angiogenesis gene expression in synovium from patients with rheumatoid arthritis. Arthritis Rheum 58:1590-1600 (Pubitemid 351847512)
24. Osterholm C, Folkersen L, Lengquist M, Ponten F, Renne T et al (2013) Increased expression of heparanase in symptomatic carotid atherosclerosis. Atherosclerosis 226:67-73
25. Rao G, Ding HG, Huang W, Le D, Maxhimer JB et al (2011) Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis. Diabetologia 54:1527-1538
26. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I et al (2007) Heparanase upregulation by colonic epithelium in inflammatory bowel disease. Mod Pathol 20:8-14 (Pubitemid 44967944)
27. Zhang S, Qing Q, Wang Q, Xu J, Zhi F et al (2013) Syndecan-1 and heparanase: potential markers for activity evaluation and differential diagnosis of Crohn's disease. Inflamm Bowel Dis 19:1025-1033
28. Zcharia E, Metzger S, Chajek-Shaul T, Aingorn H, Elkin M et al (2004) Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior. Faseb J 18:252-263 (Pubitemid 38186244)
29. Stanley PL, Steiner S, Havens M, Tramposch KM (1991) Mouse skin inflammation induced by multiple topical applications of 12-O- tetradecanoylphorbol-13-acetate. Skin Pharmacol 4:262-271
30. Petersen TK (2006) In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery. Basic Clin Pharmacol Toxicol 99:104-115 (Pubitemid 44213938)
31. Alford JG, Stanley PL, Todderud G, Tramposch KM (1992) Temporal infiltration of leukocyte subsets into mouse skin inflamed with phorbol ester. Agents Actions 37:260-267 (Pubitemid 23062755)
32. Kelly T, Miao HQ, Yang Y, Navarro E, Kussie P et al (2003) High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res 63:8749-8756 (Pubitemid 38064053)
33. Hvid H, Teige I, Kvist PH, Svensson L, Kemp K (2008) TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 20:1097-1106
34. van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N et al (2006) Increased expression of heparanase in overt diabetic nephropathy. Kidney Int 70:2100-2108 (Pubitemid 44871372)
35. Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S et al (2005) Heparanase regulates murine hair growth. Am J Pathol 166:999-1008 (Pubitemid 40524425)
36. Abou ELEM, Nagui N, Mahgoub D, El-Eishi N, Fawzy M et al (2010) Expression of cyclin D1 and p16 in psoriasis before and after phototherapy. Clin Exp Dermatol 35:781-785
37. Wagner P, Koch M, Nummer D, Palm S, Galindo L et al (2008) Detection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer. Ann Surg Oncol 15:2310-2317
38. Sano S, Chan KS, DiGiovanni J (2008) Impact of Stat3 activation upon skin biology: a dichotomy of its role between homeostasis and diseases. J Dermatol Sci 50:1-14 (Pubitemid 351249893)
39. Cohen-Kaplan V, Jrbashyan J, Yanir Y, Naroditsky I, Ben-Izhak O, et al. (2011) Heparanase induces STAT protein phosphorylation: pre-clinical and clinical significance in head and neck cancer. J Biol Chem 287:6668-6678
40. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE et al (2009) Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 41:199-204
41. Nestle FO, Conrad C (2004) The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis. J Invest Dermatol 123: xiv-xv
42. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C et al (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356:580-592 (Pubitemid 46220818)
43. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R et al (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362:118-128
44. Parham C, Chirica M, Timans J, Vaisberg E, Travis M et al (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168:5699-5708 (Pubitemid 34556153)
45. Guo D, Dunbar JD, Yang CH, Pfeffer LM, Donner DB (1998) Induction of Jak/STAT signaling by activation of the type 1 TNF receptor. J Immunol 160:2742-2750 (Pubitemid 28136727)
46. Jarnicki A, Putoczki T, Ernst M (2010) Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling? Cell Div 5:14
47. Wang H, Peters T, Sindrilaru A, Scharffetter-Kochanek K (2009) Key role of macrophages in the pathogenesis of CD18 hypomorphic murine model of psoriasis. J Invest Dermatol 129:1100-1114
48. Wang H, Peters T, Kess D, Sindrilaru A, Oreshkova T et al (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J Clin Invest 116:2105-2114 (Pubitemid 44162319)
49. Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, Nograles KE, Pierson KC et al (2010) A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol 130:2412-2422
50. Murray PJ, Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723-737
51. Gillitzer R, Wolff K, Tong D, Muller C, Yoshimura T et al (1993) MCP-1 mRNA expression in basal keratinocytes of psoriatic lesions. J Invest Dermatol 101:127-131 (Pubitemid 23218685)
52. Nickoloff BJ (2000) Characterization of lymphocyte-dependent angiogenesis using a SCID mouse: human skin model of psoriasis. J Investig Dermatol Symp Proc 5:67-73 (Pubitemid 32044092)
53. Stratis A, Pasparakis M, Rupec RA, Markur D, Hartmann K et al (2006) Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 116:2094-2104 (Pubitemid 44162318)
54. Starkey PM, Turley L, Gordon S (1987) The mouse macrophage-specific glycoprotein defined by monoclonal antibody F4/80: characterization, biosynthesis and demonstration of a rat analogue. Immunology 60:117-122 (Pubitemid 17230149)
55. Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 25:295-305 (Pubitemid 38610353)
56. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Ilan N (2003) Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 308:885-891 (Pubitemid 36976542)
57. McKenzie E, Young K, Hircock M, Bennett J, Bhaman M et al (2003) Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 373:423-435 (Pubitemid 36897845)
58. Abboud-Jarrous G, Atzmon R, Peretz T, Palermo C, Gadea BB et al (2008) Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J Biol Chem 283:18167-18176
59. Bylaite M, Moussali H, Marciukaitiene I, Ruzicka T, Walz M (2006) Expression of cathepsin L and its inhibitor hurpin in inflammatory and neoplastic skin diseases. Exp Dermatol 15:110-118
60. Fiebiger E, Maehr R, Villadangos J, Weber E, Erickson A et al (2002) Invariant chain controls the activity of extracellular cathepsin L. J Exp Med 196:1263-1269 (Pubitemid 35304191)
61. Swindell WR, Johnston A, Carbajal S, Han G, Wohn C et al (2011) Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis. PLoS One 6:e18266
62. Hermano E, Lerner I, Elkin M (2012) Heparanase enzyme in chronic inflammatory bowel disease and colon cancer. Cell Mol Life Sci 15:2501-2513
63. Akbarshahi H, Axelsson JB, Said K, Malmstrom A, Fischer H et al (2011) TLR4 dependent heparan sulphate-induced pancreatic inflammatory response is IRF3-mediated. J Transl Med 9:219
64. Brunn GJ, Bungum MK, Johnson GB, Platt JL (2005) Conditional signaling by Toll-like receptor 4. Faseb J 19:872-874 (Pubitemid 40617413)
65. Blich M, Golan A, Arvatz G, Sebbag A, Shafat I et al (2013) Macrophage activation by Heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression. Arterioscler Thromb Vasc Biol 33:56-65
66. Lowes MA, Kikuchi T, Fuentes-Duculan J, Cardinale I, Zaba LC et al (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128:1207-1211 (Pubitemid 351543220)
67. Haider AS, Lowes MA, Suarez-Farinas M, Zaba LC, Cardinale I et al (2008) Identification of cellular pathways of "type 1", Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 180:1913-1920
68. Perera GK, Di Meglio P, Nestle FO (2012) Psoriasis. Annu Rev Pathol 7:385-422
69. Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V et al (1991) Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 138:129-140
70. van den Oord JJ, de Wolf-Peeters C (1994) Epithelium-lining macrophages in psoriasis. Br J Dermatol 130:589-594 (Pubitemid 24204694)
71. Djemadji-Oudjiel N, Goerdt S, Kodelja V, Schmuth M, Orfanos CE (1996) Immunohistochemical identification of type II alternatively activated dendritic macrophages (RM 3/1 + 3, MS-1+/-, 25F9-) in psoriatic dermis. Arch Dermatol Res 288:757-764 (Pubitemid 26388134)
72. Vestergaard C, Just H, Baumgartner Nielsen J, Thestrup-Pedersen K, Deleuran M (2004) Expression of CCR2 on monocytes and macrophages in chronically inflamed skin in atopic dermatitis and psoriasis. Acta Derm Venereol 84:353-358 (Pubitemid 39312267)
73. Boehncke WH, Wortmann S, Kaufmann R, Mielke V, Sterry W (1995) A subset of macrophages located along the basement membrane ("lining cells") is a characteristic histopathological feature of psoriasis. Am J Dermatopathol 17:139-144
74. Kawada A, Hara K, Kominami E, Hiruma M, Noguchi H et al (1997) Processing of cathepsins L, B and D in psoriatic epidermis. Arch Dermatol Res 289:87-93 (Pubitemid 27075573)
75. Elkin M, Ilan N, Ishai-Michaeli R, Friedmann Y, Papo O et al (2001) Heparanase as mediator of angiogenesis: mode of action. Faseb J 15:1661-1663
76. Ramani VC, Purushothaman A, Stewart MD, Thompson CA, Vlodavsky I et al (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280:2294-2306